Beijing News (reporter Wang Kara) on June 21, Lizhu Group issued an announcement that the fluvoxamine maleate tablets of lizhu pharmaceutical factory, a wholly-owned subsidiary, passed the consistency evaluation, which is also the only competitor of the original research drug in China. Up to now, Livzon Group has invested about 7.0735 million yuan in direct research and development costs for the consistency evaluation of fluvoxamine maleate tablets.
Fluvoxamine maleate tablets are selective 5-HT reuptake inhibitors that are indicated for the treatment of depression and related symptoms as well as for the treatment of symptoms of obsessive-compulsive disorder. Developed by Abbott Pharmaceuticals, the drug was approved in the United States in 1994 and entered China in 2000. Fluvoxamine maleate tablets are the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog" varieties, and the indications are depression and obsessive-compulsive disorder.
According to IQVIA sampling statistical estimates, the terminal sales amount of domestic fluvoxamine maleate tablets in 2020 is about 237 million yuan. According to intranet data, in the market of fluvoxamine maleate tablets in China's public medical institutions, the share of Livzon Group rose from 49.19% in 2013 to 56.88% in 2017, and sales revenue grew rapidly, successfully exceeding 100 million yuan in 2018. In 2019, the sales of Fluvoxamine maleate tablets of Livzon Group were 129 million yuan, an increase of 26.28% year-on-year; in 2020, the sales revenue reached 171 million yuan, and the original drug market was further squeezed.
Proofreading By Chen Diyan
![Strong Sha Ming, our learning example Author: Zhang Suolong[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)